Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib by Oliveras-Ferraros, Cristina et al.
In the previous issue of Breast Cancer Research, Jin and 
colleagues [1] demonstrated that the lipogenic enzyme 
fatty acid synthase (FASN) is phosphorylated when it is 
in complex with the tyrosine kinase receptor HER2. 
HER2-dependent activating phosphorylation of FASN 
was related to tumor progression and was sensitive to the 
dual HER1/HER2 tyrosine kinase inhibitor lapatinib [1]. 
Adding to knowledge of the therapeutic value of the 
phosphorylation status of FASN in HER2-driven breast 
cancer (BC), we now provide experimental evidence that 
the expression status of FASN in the extracellular milieu 
(that is, extracellular FASN) may function as a novel 
biomarker that distinc  tively predicts molecular function-
ing of lapatinib.
AMP-activated protein kinase (AMPK)-activating 
drugs, by mimicking an elevated AMP/ATP ratio in BC 
cells, drastically augment the release of extracellular 
FASN in HER2-positive BC cells [2]. Lapatinib-induced 
deprivation of tumor cell energy activates AMPK to 
trigger an entire cascade of metabolic events, including 
suppression of FASN expression and activity [1,3]. We 
hypothesized that a diﬀ  erential ability to initiate AMPK-
sensed metabolic stress responses may provide informa-
tion about the eﬃ     cacy of HER-targeting drugs via 
changes in the extracellular FASN status. Enzyme-linked 
immunosorbent assay (ELISA)-based quantitative 
analyses revealed that lapatinib treat  ment drastically 
enhanced extracellular FASN con  cen  tration (by at least 
8.0-fold) (Figure 1a). Immuno  blotting assessment of 
AMPK phosphorylation at Th  r172  conﬁ  rmed  that 
lapatinib treatment induced a strong activation of AMPK 
(Figure 1b). A weak but detectable upregulation of PP-
AMPKTh  r172 was observed upon treatment with geﬁ  tinib. 
Trastuzumab, cetuximab, and erlotinib – all of which are 
unable to promote FASN release – failed to activate 
AMPK. AMPK knockdown using short interfering RNA 
(siRNA) transfection [2] fully prevented lapatinib-
induced FASN release (Figure S1). Immunoblotting and 
cell imaging analyses conﬁ  rmed that FASN was depleted 
from the cytosol of lapatinib-treated HER2 over  expres-
sors and accumulated in their extracellular milieu 
(Figure S1).
Treatment with lapatinib dramatically increased FASN 
release (by approximately 17 times) in lapatinib-responsive 
SKBR3 TzbR cells (Figure 1c), which were selected for 
long-term outgrowth in trastuzumab-containing culture 
medium. Extracellular FASN remained unaltered in res-
ponse to trastuzumab or lapatinib in JIMT-1 BC cells, 
which exhibit de novo cross-refractoriness to multiple 
HER1/2-targeted therapies (Figure 1c). Lapatinib treat-
ment signiﬁ   cantly activated AMPK and promoted an 
enormous accumulation of extracellular FASN in 
lapatinib-hypersensitive MCF-7/HER2 cells (Figure 1d). 
Equimolar concentrations of lapatinib failed to activate 
AMPK or to alter FASN release into the extracellular 
milieu of MCF-7/HER2 LapR cells, which were obtained 
by continuously subculturing parental MCF-7/HER2 
cells with high-dose lapatinib.
High levels of circulating FASN can be found in 
peripheral blood of HER2-overexpressing BC patients 
[4]. Th   e exclusive ability of lapatinib to actively promote 
the extracellular release of FASN via AMPK-sensed 
energy depletion in metabolically demanding HER2-
driven BC cell growth might provide a molecular 
rationale to evaluate the predictive value of circulating 
FASN in HER2-positive BC patients receiving lapatinib.
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Figure 1. Lapatinib’s molecular functioning involves AMPK-dependent release of extracellular fatty acid synthase (FASN). (a) HER1 or 
HER2 inhibitors (or both) diff  erentially regulate extracellular expression of FASN. FASN concentration in cell culture supernatants from SKBR3 
cells cultured in low-serum (0.5% fetal bovine serum)-containing Dulbecco’s modifi  ed Eagle’s medium in the presence or absence of cetuximab 
(100 μg/mL), trastuzumab (100 μg/mL), erlotinib (1 μmol/L), gefi  tinib (1 μmol/L), or lapatinib (1 μmol/L) for 48 hours was measured by enzyme-
linked immunosorbent assay (ELISA) as described elsewhere [2]. (b) HER1 or HER2 inhibitors (or both) diff  erentially regulate the activation status 
of AMPK. After the harvesting, cell cultures treated as described above were lysed and prepared for immunoblotting as described elsewhere 
[2]. A representative immunoblotting analysis obtained by using the AMPK Antibody Kit (Cell Signaling Technology, Inc., Danvers, MA, USA) is 
shown. (c) Lapatinib treatment induces extracellular release of FASN in an AMPK-dependent manner. SKBR3 cells were transiently transfected 
with AMPK short interfering RNA (siRNA) or control siRNA or were treated with transfection reagent alone (mock) before exposure to 1 mmol/L 
lapatinib for 48 hours. The FASN-detect ELISA was then used to quantitatively assess the released concentration of FASN in the extracellular milieu 
[2]. (d) Lapatinib-induced release of extracellular FASN is related to lapatinib effi   cacy in trastuzumab-refractory breast cancer cells. (e) Lapatinib-
induced release of extracellular FASN is related to lapatinib’s molecular functioning and involves activation of AMPK. Results in graphs are means 
(columns) and 95% confi  dence intervals (bars) of two independent experiments made in triplicate. Statistically signifi  cant diff  erences (one-factor 
analysis of variance [ANOVA]) between experimental conditions and unsupplemented control cells are shown by asterisks (*P <0.01, **P <0.001; n.s., 
not statistically signifi  cant). All statistical tests were two-sided. AMPK, AMP-activated protein kinase.
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Figure S1. Lapatinib treatment promotes the release of two 
extracellular forms of fatty acid synthase (FASN). Left: Extracellular 
expression of FASN in SKBR3 cultures exposed to serum starvation 
(lower panels) or 1 μmol/L lapatinib (upper panels) for 0, 6, 24, and 
48 hours was monitored by immunoblotting procedures using 
three monoclonal anti-FASN antibodies (Abs) as specifi  ed [2]. FASN1 
indicates the high-molecular-mass (260 kDa) form of FASN, and 
FASN2 indicates the intermediate-size (150 kDa) form of FASN. The 
clone M3 (1:2,000 dilution), a mouse anti-FASN monoclonal antibody 
(kindly provided by Ellen Pizer, Johns Hopkins University, Baltimore, 
MD, USA) diluted 1:5,000; the clone 23 (1:250 dilution), a mouse 
anti-FASN monoclonal antibody obtained from BD Biosciences 
Pharmingen (San Diego, CA, USA); and the clone 3B3-1D6 (1:250 
dilution), a mouse anti-FASN monoclonal antibody (M02) obtained 
from Abnova (Taipei, Taiwan), were used. Right: Images of FASN 
expression in whole SKBR3 cell cultures before and after treatment 
with 1 μmol/L lapatinib were captured as a 4-by-4 montage on a 
BD Pathway™ 855 BioImager System (BD Biosciences Pharmingen). 
Two diff  erent channels for Alexa Fluor 488 (pseudo-colored red: 
FASN) and Hoechst 33342 (pseudo-colored blue: nuclei) were used. 
Images were captured with a 20× objective (NA 075; Olympus, Tokyo, 
Japan) in accordance with the recommended assay procedure and 
were merged by means of BD Attovision™ software (BD Biosciences 
Pharmingen). A schematic depicting a model of the relationship 
between lapatinib-responsive, AMP-activated protein kinase (AMPK)-
sensed cellular energy status and extracellular release of FASN in 
HER2-positive breast cancer cells is shown.
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